Bone Density in Asthmatic Patients Taking Inhaled Corticosteroids: Comparison of Budesonide and Beclomethasone Dipropionate
Bone Density in Asthmatic Patients Taking Inhaled Corticosteroids: Comparison of Budesonide and Beclomethasone Dipropionate
复制标题
服用吸入皮质类固醇的哮喘患者的骨密度：布地奈德和二丙酸倍氯米松的比较
DOI：
--
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
J. G. Douglas
中科院分区：
文献类型：
--
作者：
G. Packe;O. Robb;S. Robins;D. Reid;J. G. Douglas
我们评估了20名吸入布地奈德（BUD）（中位日剂量800 μg）超过一年的哮喘患者的骨矿物质密度（BMD），其中13名患者曾接受过全身性类固醇治疗。他们的结果与20名接受吸入性高剂量二丙酸倍氯米松（BDP）（中位日剂量1，000 μg）的患者进行了比较，所有患者均接受过全身性皮质类固醇治疗，并与17名从未接受过吸入性或全身性类固醇治疗的轻度哮喘患者进行了比较。服用BUD的患者的平均（标准差）（SD）BMD为139.5（28.6）mg/ml。这显著低于（p < 0.05）从未吸入或全身使用类固醇的对照患者（160.4（27.4）mg/ml）。服用BUD的患者的平均BMD与服用BDP的患者的平均BMD（127.5（22.6）mg/ml）无显著差异。尽管定期服用高剂量BUD的哮喘患者的BMD降低可能是由于先前的皮质类固醇疗程，但骨丢失的程度与服用高剂量吸入BDP和间歇性皮质类固醇的患者相似。
We assessed bone mineral density (BMD) in 20 asthmatics who had been taking inhaled budesonide (BUD) (median daily dose 800 μg) for over a year, 13 of whom had taken previous courses of systemic steroids. Their results were compared with those of 20 patients receiving inhaled high-dose beclomethasone dipropionate (BDP) (median daily dose 1,000 μg), all of whom had received previous courses of systemic corticosteroids, and with those of 17 mild asthmatics who had never taken either inhaled or systemic steroids. Mean (standard deviation) (SD)) BMD in the patients taking BUD was 139.5 (28.6) mg/ml. This was significantly lower (p < 0.05) than in the control patients who had never taken inhaled or systemic steroids (160.4 (27.4) mg/ml). Mean BMD in the patients taking BUD did not differ significantly from that observed in patients taking BDP (127.5 (22.6) mg/ml). Although the reduction in BMD in the asthma patients taking regular high-dose BUD could have been due to previous courses of corticosteroid, the magnitude of bone loss is similar to that seen in patients taking high-dose inhaled BDP and intermittent corticosteroids.